Memento Medicines launched with a focus on ophthalmology and secured a $93 million Series A financing tied to licensing a lead program for retinal diseases. The company’s launch structure centers on using the funds to advance the retinal asset under an initial licensing arrangement. The move reflects continued investor focus on ophthalmic development, where biomarker-driven endpoints and defined patient populations can support clinical development strategies. Retinal disease pipelines also benefit from established delivery routes and measurable functional assessments. While details on the program and target patient groups were limited in the announcement, the capital injection positions Memento Medicines to build early clinical momentum. For the market, the funding adds to the steady flow of capital into specialty biotech categories positioned for clearer clinical milestones.